Pharmaceutical Stability and Storage Services Market Report 2025

The pharmaceutical stability and storage services market size has grown strongly in recent years. It will grow from $2.66 billion in 2024 to $2.81 billion in 2025 at a compound annual growth rate (CAGR) of 5.8%. The growth in the historic period can be attributed to the increasing demand for biologics, increasing prevalence of chronic diseases, growth in drug development, increasing complexity of drug formulations, and growing research and development in pharmaceuticals.

The pharmaceutical stability and storage services market size is expected to see strong growth in the next few years. It will grow to $3.57 billion in 2029 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to rising personalized medicine, increasing cold chain logistics, expanding biopharma pipelines, rising biologic drug approvals, and growing demand for stability testing. Major trends in the forecast period include technological advancements, advancements in cryogenic storage technologies, development in digital monitoring technologies, development of innovative packaging technologies, and advanced temperature-controlled storage systems.

The forecast of 6.1% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper U.S. drug developers by increasing the cost of compliant stability testing and cold chain storage services from providers in the UK and Switzerland, thereby prolonging regulatory approvals and raising research and development overhead. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing number of novel drug approvals is expected to drive the expansion of the pharmaceutical stability and storage services market in the future. A novel drug is a newly developed pharmaceutical compound that has not been previously approved for use or marketed. The surge in novel drug approvals is largely attributed to advancements in biotechnology, which have enabled the discovery of new compounds, as well as improvements in regulatory processes that facilitate faster and more efficient drug development. The increase in novel drug approvals boosts the demand for pharmaceutical stability and storage services, which ensure the proper conditions, compliance, and extended shelf-life management of these products. For example, in October 2023, the U.S. Food and Drug Administration (FDA) reported that 37 novel drugs were approved in 2022, followed by 50 in 2024, advancing treatments in areas such as cancer, rare diseases, neurology, infections, and conditions such as schizophrenia, pain, and Alzheimer’s. As such, the rising number of novel drug approvals is fueling the growth of the pharmaceutical stability and storage services market.

Leading companies in the pharmaceutical stability and storage services market are focusing on the development of technologically advanced solutions, such as cryogenic storage suites, to improve the preservation of temperature-sensitive pharmaceutical products. Cryogenic storage suites are specialized facilities that maintain extremely low temperatures, typically below -150°C, to preserve temperature-sensitive biological and pharmaceutical materials such as cell therapies, vaccines, and biologics. For instance, in December 2024, Astoriom, a UK-based stability and biospecimen storage company, unveiled a cryogenic storage suite at its Tramore facility in County Waterford, Ireland. This expansion significantly enhances its capacity to store biological samples, offering precise temperature control down to -196°C, large storage capacity, ISO 9001 certification for regulatory compliance, and advanced security features, such as access controls and monitoring systems, to ensure safe long-term preservation.

In June 2022, Cambrex Corporation, a US-based contract development and manufacturing organization, acquired Q1 Scientific for an undisclosed amount. This acquisition allows Cambrex to expand its presence in Europe, bolster its stability storage service capabilities, and strengthen its portfolio of outsourced pharmaceutical solutions to meet the growing demands of the industry. Q1 Scientific Limited, based in Ireland, specializes in providing pharmaceutical stability and storage services.

Major players in the pharmaceutical stability and storage services market are Cencora Inc, SGS S.A., Eurofins Scientific SE, Catalent Inc, Charles River Laboratories, Intertek Group plc, Element Materials Technology Inc, Alloga UK Ltd., ALS Limited, Pharmaceutical Contract Industries Pharma Services., Almac Group, Alcami Corporation, BioLife Solutions Inc., Auriga Research Private Limited, Reading Scientific Services Ltd., Lucideon Limited, Q Laboratories Inc, PD Partners, Precision Stability Storage, Roylance Stability Storage Limited.

North America was the largest region in the pharmaceutical stability and storage services market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in pharmaceutical stability and storage services report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the pharmaceutical stability and storage services market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The pharmaceutical stability and storage services market consists of revenues earned by entities by providing services such as photostability testing, cold chain management, disaster recovery and backup storage. The market value includes the value of related goods sold by the service provider or included within the service offering. The pharmaceutical stability and storage services market also includes sales of stability chambers, cryogenic storage systems, cold storage units and automated sample management systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The pharmaceutical stability and storage services market research report is one of a series of new reports that provides pharmaceutical stability and storage services market statistics, including pharmaceutical stability and storage services industry global market size, regional shares, competitors with a pharmaceutical stability and storage services market share, detailed pharmaceutical stability and storage services market segments, market trends and opportunities, and any further data you may need to thrive in the pharmaceutical stability and storage services industry. This pharmaceutical stability and storage services market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Pharmaceutical stability and storage services are specialized offerings designed to ensure that pharmaceutical products, including drugs, medications, and vaccines, retain their quality, efficacy, and safety throughout their shelf life. These services involve maintaining controlled storage environments, conducting stability studies to monitor chemical, physical, and microbiological changes, and ensuring compliance with regulatory standards.

The primary pharmaceutical stability and storage services include stability testing and storage solutions. Stability services evaluate how pharmaceutical products maintain their quality, potency, and safety under varying environmental conditions over time. These services apply to various products such as tablets, capsules, injectable solutions, oral suspensions, combination products, and others, and can involve both small and large molecules. Stability and storage services are provided through in-house and outsourcing models, and are utilized by biopharmaceutical companies, contract manufacturing organizations, contract research organizations, and other entities.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.